Repligen

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Repligen (RGEN) reports strong 2022 performance, eyes growth amid challenges

Repligen anticipates a challenging yet optimistic year in 2023, with revenue guidance of $760-800 million and adjusted EPS of $2.61-2.69 per fully diluted share. The company remains focused on organic growth, innovation, and strategic acquisitions to navigate industry headwinds.

Repligen reports Q1 revenue growth, eyes China rebound and new products

Repligen's Q1 2023 performance saw revenue growth but overall revenues declined due to reduced COVID-related demand.
Despite challenges in China and revised guidance, strategic investments and confidence in future growth opportunities remain strong.
The company is focused on new product launches, pricing resilience, and addressing challenges to drive growth and margin improvement.

Repligen faces revenue decline and margin pressure, eyes growth strategies

Repligen faces challenges in revenue decline and margin compression but is focusing on cost control and new product launches for growth.
Diversified revenue streams and positive developments in orders and integration provide a foundation for future opportunities.
Market dynamics and pharma spend challenges pose uncertainties, but the company remains optimistic about growth prospects.
Visibility improvements, margin recovery expectations, and pricing strategies are key focus areas for future profitability.

Repligen sees recovery in Q3 amidst industry challenges and restructuring

Repligen's Q3 2023 showed signs of recovery amidst industry challenges, with a focus on cost optimization and new product launches. The company incurred restructuring charges to streamline operations and expects improved margins in 2024. Despite revenue declines, opportunities lie in the gene therapy segment and future recovery in China.

Repligen reports Q4 revenue decline but eyes growth in China

Repligen's Q4 2023 showed mixed results with revenue decline but sequential growth. The company is focusing on profitability improvements in 2024 and anticipates growth driven by new modalities and market recovery. Challenges in revenue performance are being addressed, with a strategic focus on key account management and cost containment.

Repligen reports mixed Q1 results, focuses on innovation and growth

Repligen's Q1 2024 performance showed mixed results with revenue declines but positive growth in key segments. The company maintains its focus on innovation, cost control, and strategic expansion while navigating challenges in profitability. Opportunities lie in market improvements and growth potential in new modalities.

Repligen reports strong Q2 performance, eyes robust growth ahead

Repligen's Q2 2024 earnings call showcased strong performance in pharma and consumables, despite challenges from China and foreign exchange. The company anticipates a return to robust revenue growth in the second half of the year and is optimistic about future growth prospects.

Repligen (RGEN) reports robust Q3 results and eyes 2025 growth

Repligen is on track to meet 2024 revenue guidance, entering 2025 in a strong position.
Exciting product launches planned for 2025 across all business units.
Strong start to Q4 with confidence in meeting financial targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

The life sciences company reported better-than-expected second-quarter results.

Why Repligen Stock Soared This Week

Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. The company also raises its guidance for 2021.

Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View

Repligen Corp, Inc. (RGEN) CEO Anthony Hunt on Q1 2021 Results - Earnings Call Transcript

Repligen (RGEN) delivered earnings and revenue surprises of 49.06% and 12.26%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Q2 Earnings and Revenues Surpass Estimates

Shares of Repligen (NASDAQ:RGEN) moved higher by 0.0% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 88.10% over the past year to $0.79, which beat the estimate of $0.52.

Recap: Repligen Q2 Earnings

WALTHAM, Mass., July 27, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2021. Provided in this press release are financial highlights for the three- and six- month periods ended June 30, 2021, updates to our financial guidance for the fiscal year 2021 and access information for today's webcast and conference call.

Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance

Repligen (NASDAQ:RGEN) announces its next round of earnings this Tuesday, July 27. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.

Earnings Outlook For Repligen

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth

Webcast and Conference Call to Be Held Tuesday, July 27, 2021 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Tuesday, July 27, 2021 at 8:30 a.m. EDT

Repligen to Report Second Quarter 2021 Financial Results

Amgen

Biogen

BioNTech SE

Moderna

Intellia Therapeutics

Regeneron Pharmaceuticals

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

3 Biotech Stocks Poised to Gain in the Second Half of 2021

Repligen Corporation (NASDAQ: RGEN) has agreed to acquire France-based Polymem S.A., a provider of hollow fiber membranes and modules.

Repligen To Buy Polymem For An Undisclosed Sum

WALTHAM, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Toulouse, France based Polymem S.A. (“Polymem”), a leading industrial expert in the development and manufacture of hollow fiber membranes and modules.

Repligen Corporation Announces Agreement to Acquire Polymem S.A.

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Repligen (RGEN) Down 8.4% Since Last Earnings Report: Can It Rebound?

Novartis

CureVac B.V

Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.

Novartis (NVS) & Molecular Partners Initiate Study for COVID-19

Ovid Therapeutics

3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem

Repligen (RGEN) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

Repligen (RGEN) Enters Oversold Territory

Vipshop Hlds

The current system has created a tremendous wealth gap in America. Which is why I've decided to tackle it head on.

The Power of a Great System

Apple

Century Communities

DaVita

Herbalife

Herbalife (HLF), DaVita (DVA), Apple (AAPL), Century Communities (CCS) & Repligen (RGEN) are the top stocks that flaunt attractive earnings growth at present.

5 of the Best Stocks to Buy Now for Striking Earnings Growth

Repligen Corporation's (RGEN) CEO Tony Hunt on Q1 2021 Results - Earnings Call Transcript

Repligen (RGEN) reports encouraging first-quarter results with sales and earnings beating estimates. The company also raises its guidance for 2021.

Repligen (RGEN) Beats on Q1 Earnings & Sales, Raises 2021 View

Repligen (RGEN) delivered earnings and revenue surprises of 58.14% and 22.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates

The stock price of Repligen Corporation (NASDAQ: RGEN) increased from $208.11 to $216.50 (up 4.03%) pre-market. This is why it happened.

RGEN Stock: From $208.11 To $216.50 (4.03% Increase) Pre-Market Explanation

Shares of Repligen (NASDAQ:RGEN) moved higher by 7.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 112.50% over the past year to $0.68, which beat the estimate of $0.42.

Repligen: Q1 Earnings Insights

WALTHAM, Mass., May 04, 2021 (GLOBE NEWSWIRE) --  Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2021. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2021, and access information for today's webcast and conference call.

Repligen Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance

Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT Webcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT

News for Repligen Stock (RGEN)